ArticleAdvances in experimental medicine and biology2021
Lipid Metabolism in Tumor-Associated Myeloid-Derived Suppressor Cells.
Article in Advances in experimental medicine and biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.
- The role of lipid metabolic reprogramming in tumor microenvironment.Theranostics · 2023Pooled it
- The Cxcr2Frontiers in immunology · 2023Article
- A Novel Risk Model Based on Lipid Metabolism-Associated Genes Predicts Prognosis and Indicates Immune Microenvironment in Breast Cancer.Frontiers in cell and developmental biology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myeloid-derived suppressor cells (MDSCs) are a heterogenous population of myeloid cells with immature phenotypes and immunosuppressive functions. This population of cells has been extensively studied over the past decade owing to an increasing recognition of their pivotal role in pathological conditions including cancers, infectious diseases, sepsis, and autoimmune diseases. Various treatments targeting MDSCs are currently under development or in clinical trials with the aim to restore functional immunity against tumors or pathogens. Recent advances in immune metabolism demonstrate the role of metabolic pathways, especially lipid metabolism, in the differentiation and function of MDSCs in tumor environments. Therefore, a comprehensive understanding of lipid metabolism in MDSCs would facilitate the development of novel therapies against tumors through metabolic reprograming of MDSCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.